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Purpose: This study was performed to investigate the relationship between cyclo-
oxygenase-2 (COX-2) expression and apoptosis/angiogenesis in inflammatory and non-
inflammatory benign prostatic hyperplasia (BPH) and prostate cancer (PC).
Materials and Methods: This study involved 64 BPH and 57 PC patients. The BPH histo-
pathologies were classified by the presence of chronic inflammation as follows: non-
inflammatory BPH (NI-BPH; n=23) and inflammatory BPH (I-BPH; n=41). The associ-
ation between the expression of COX-2, expression of Bcl-2, the apoptotic index (AI), 
expression of vascular endothelial growth factor (VEGF), and microvascular density 
(MVD) in the prostate was investigated.
Results: An overexpression of COX-2, Bcl-2, and VEGF was observed in cases of PC 
compared with cases of BPH. In PC, the AI was lower and MVD was higher than in 
BPH. In NI-BPH, I-BPH, and PC, the overexpression of COX-2, Bcl-2, and VEGF gradu-
ally increased. The AI was high in I-BPH, but did not differ significantly between the 
NI-BPH and I-BPH groups or between the NI-BPH and PC groups. MVD was sig-
nificantly high in PC, but no significant difference was found between NI-BPH and 
I-BPH. A significant correlation was shown between the overexpression of COX-2 and 
Bcl-2, and COX-2 and VEGF. However, the AI was not correlated with the over-
expression of COX-2 or Bcl-2. MVD was correlated with the overexpression of COX-2 
and VEGF.
Conclusions: COX-2 overexpression in PC is correlated with a decrease in apoptosis 
and an increase in angiogenesis. Chronic inflammation in BPH causes an over-
expression of COX-2, which induces the increased expression of Bcl-2 and VEGF. It is 
likely that chronic inflammation plays a role in the intermediate step of carcinogenesis 
in the prostate.
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INTRODUCTION
Prostate cancer (PC) is the most common malignancy 
among men in Western nations and is the second leading 
cause of cancer-related death in the United States, with in-
creasing rates being reported in Korea [1,2]. However, the 
etiology of PC is not yet clearly identified. Among the many 
causes of cancer, it is well established that the link between 
chronic inflammation and cancer involves cytokines and 
mediators of inflammatory pathways, which act during the Korean J Urol 2011;52:253-259
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various steps of tumorigenesis [3]. In addition, histologic, 
molecular genetic, and epidemiologic evidence strongly 
suggests that inflammation and infection are important in 
the etiology of PC [3-5].
　The cyclooxygenases (COXs) are a family of enzymes that 
catalyze the rate-limiting step of prostaglandin biosyn-
thesis. COX-2 may play a key role in the tumorigenesis of 
a variety of human malignancies by stimulating cell pro-
liferation and angiogenesis, inhibiting epithelial differ-
entiation, enhancing cell invasiveness and tumor meta-
stasis, inhibiting apoptosis, mediating immune sup-
pression, and increasing the production of mutagens [6-8]. 
The expression of COX-2 in prostate tissues or PC has been 
the subject of many recent studies [4,5,9]. Several such 
have examined the expression of COX-2 in post-atrophic 
hyperplasia, proliferative inflammatory atrophy, and 
prostate intraepithelial neoplasia, but the results are still 
controversial [9-13].
　To the best of our knowledge, there has been little re-
search carried out on the role of COX-2 expression in the 
chronic inflammation of normal prostatic glands. We 
therefore compared the overexpression of COX-2 in non-
inflammatory benign prostatic hyperplasia (NI-BPH), in-
flammatory benign prostatic hyperplasia (I-BPH), and PC. 
In addition, we investigated the relationships between 
COX-2 overexpression and both angiogenesis and apop-
tosis.
MATERIALS AND METHODS
We evaluated apoptosis by two immunohistochemical 
methods. We assessed Bcl-2 expression, which exerts an 
anti-apoptotic effect in the intrinsic pathway of apoptosis. 
Second, we determined the apoptotic index by the terminal 
deoxynucleotidyl transferase nick end labeling (TUNEL) 
assay, which revealed DNA fragmentation. Similarly, we 
evaluated angiogenesis by two immunohistochemical in-
dexes: vascular endothelial growth factor (VEGF), which 
is the most potent tumor angiogenic factor, and micro-
vascular density (MVD), which reflects the angiogenic vas-
culature present.
1. Tissue samples
The tissue samples used in this study were obtained from 
the files of the Department of Urology, Keimyung 
University Dongsan Medical Center, during the period of 
2005 to 2009. A total of 121 BPH and PC patients were in-
cluded in this study. Specimens were obtained from 57 PC 
patients who underwent radical prostatectomy and 64 
BPH patients who underwent transurethral resection of 
prostate (TURP). The BPH histopathologies were classi-
fied by the presence of chronic inflammation (infiltration 
of macrophages, lymphocytes, and plasma cells) as follows: 
NI-BPH (n=23) and I-BPH (n=41). 
2. Tissue microarray
Tissue microarray was constructed from formalin-fixed 
paraffin-embedded prostate tissue specimens from 121 
cases. In each sample, the part comprising NI-BPH, I-BPH, 
or PC was selected by light-microscopic examination and 
was used for tissue microarray. Cores measuring 0.3 cm in 
diameter were taken from the donor paraffin blocks and 
were then rearranged in the recipient paraffin blocks by us-
ing a manual tissue arrayer (MTA-1, Beecher Instruments, 
Sun Prairie, WI, USA).
3. Immunohistochemical analysis
Conventional 4 μm sections were obtained from the tissue 
microarray blocks and incubated in an oven at 60
oC 
overnight. Sections were then dewaxed in xylene for 10 mi-
nutes and rehydrated through graded alcohol to distilled 
water. The activity of endogenous peroxidases was blocked 
with 3% hydrogen peroxide in methanol for 15 minutes. 
Subsequently, sections were subjected to antigen retrieval 
by microwaving at high power in 10 mM citrate buffer (pH 
6.0) for 15 minutes. The primary antibodies used were 
COX-2 (160112; Cayman Chemical Co., Ann Arbor, MI, 
USA; 1:400), Bcl-2 (18-0193; Zymed, San Francisco, CA, 
USA; 1:800), and VEGF (SC-7269; Santa Cruz Biotechno-
logy, Santa Cruz, CA, USA, 1:1,000). All slides were stained 
by use of a Lab Vision Autostainer 360 (Lab Vision, Fre-
mont, CA, USA). 
4. TUNEL assay
In the histologic sections, fragmented nuclear DNA associ-
ated with apoptosis was labeled by TUNEL [14] with an 
ApopTag
Ⓡ peroxidase in situ apoptosis detection kit (S7100, 
Chemicon, Temecula, CA, USA) according to the manu-
facturer's instructions. Briefly, after deparaffinization and 
blocking of endogenous peroxidase with 3% H2O2 in distilled 
water for 5 minutes, sections were incubated with 20 g/ml 
proteinase K for 20 minutes. After prehybridization treat-
ment, sections were incubated with TdT and dUTP-digox-
igenin for 60 minutes at 37
oC. Incubation with anti-digox-
igenin antibody-peroxidase for 30 minutes was used to de-
tect dUTP-digoxigenin labeling, followed by color develop-
ment with a solution containing 3,3'-diaminobenzidine. 
Hematoxylin was used for counterstaining.
5. Interpretation
Immunohistochemical staining for COX-2, VEGF, and 
Bcl-2 was interpreted as positive if any portion of cancer 
cells or epithelial cells within a prostate gland showed cyto-
plasmic immunoreactivity. Scoring was performed by 2 in-
dependent pathologists, after reaching consensus, by us-
ing a multi-headed microscope. To highlight tumor micro-
vessels, endothelial cells were stained for CD34. The dens-
est vascular areas were identified by scanning tumor sec-
tions on a low-power field (x40 and x100). After identi-
fication of the densest vascularization, a vessel count was 
performed on a high-power field (x400). For interpretation 
of TUNEL staining, we counted apoptotic epithelial cells 
on a high-power field after determination of the densest 
region.Korean J Urol 2011;52:253-259
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FIG. 1. Immunohistochemistry analysis of COX-2, Bcl-2, apoptotic index, VEGF, and MVD in PC (A-E) and BPH (F-J). COX-2 (A, F),
Bcl-2 (B, G), and VEGF (D, I) were positive in cytoplasm of tumor cells or epithelial cells of BPH. They were more prominent in PC
than in BPH. CD34 for MVD was positive in cytoplasm of endothelial cells. MVD was markedly increased in PC (E) compared with
BPH (J). TUNEL stain for apoptotic index showed a nuclear pattern. Apoptotic index was lower in PC (C) than in BPH (H). COX-2:
cyclooxygenase-2, VEGF: vascular endothelial growth factor, MVD: microvascular density, BPH: benign prostatic hyperplasia, PC: 
prostate cancer.
6. Statistical analysis
Statistical analysis was carried out by using SPSS ver. 17.0 
(SPSS Inc., Chicago, IL, USA). The significance of COX-2, 
Bcl-2, and VEGF overexpression among various pathologic 
patterns was assessed by using either the Pearson chi-square 
or Mantel-Haenszel chi-square test, as appropriate. The 
Mann-Whitney U-test or Kruskal-Wallis test was used for 
the comparisons of MVD and apoptotic index. Tukey’s test 
was used for post-hoc multiple comparisons. The strength 
of association between each immunohistochemical score 
was assessed by using the Spearman correlation analysis. 
Statistical analysis was performed, with p＜0.05 consid-
ered significant.
RESULTS
1. Immunohistochemical expression in BPH and PC
The majority of BPH samples (79.7%) were negative for 
COX-2. In contrast, the PC samples were positive for COX-2 
in 57.9% of cases (p＜0.001). Similarly, an overexpression 
of Bcl-2 and VEGF was observed in PC compared with BPH 
samples (p＜0.001 and p=0.035, respectively). Further-
more, the apoptotic index was lower (1.4±2.0; p＜0.001) 
and MVD was higher (53.2±29.3; p= 0.001) in PC samples Korean J Urol 2011;52:253-259
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FIG. 2. Apoptotic index in NI-BPH, I-BPH, and PC. Statistical 
analysis showed a significant increase in the apoptotic index in
I-BPH compared with PC (p＜0.001). The apoptotic index was also
high in I-BPH compared with NI-BPH, but the difference was not
significant (p=0.050). NI-BPH: noninflammatory benign pro-
static hyperplasia, I-BPH: inflammatory benign prostatic hyper-
plasia, PC: prostate cancer, 
a: statistical analysis by Tukey test.
TABLE 1. Comparison of COX-2 expression, Bcl-2 expression, VEGF
expression, apoptotic index, and MVD between BPH and PC
BPH (n=64) PC (n=57) p-value
Positive rate n (%)
   COX-2 13 (20.3) 33 (57.9) ＜0.001
a
   Bcl-2 14 (21.9) 35 (61.4) ＜0.001
a
   VEGF 16 (25.0) 25 (43.9) 0.035
a
Positive score Mean±SD
   Apoptotic index 2.6±2.7 1.4±2.0 ＜0.001
b
   MVD 29.9±10.1 53.2±29.3 0.001
b
COX-2: cyclooxygenase-2, VEGF: vascular endothelial growth 
factor, MVD: microvascular density, BPH: benign prostatic hy-
perplasia, PC: prostate cancer, 
a: statistical analysis by Pearson 
chi-square test, 
b: statistical analysis by Student's t-test
TABLE 2. Comparison of COX-2 expression, Bcl-2 expression, 
VEGF expression, apoptotic index, and MVD between NI-BPH,
I-BPH, and PC
NI-BPH I-BPH PC
p-value
(n=23) (n=41) (n=57)
Positive rate n (%)
  COX-2   3 (13.0) 10 (24.4) 33 (57.9) ＜0.001
a
  Bcl-2   3 (13.0) 11 (26.8) 35 (61.4) ＜0.001
a
  VEGF 1 (4.3) 15 (36.6) 25 (43.9) 0.002
a
Positive score Mean±SD
  Apoptotic index 2.0±2.8   2.9±2.6 1.4±2.0 ＜0.001
b
  MVD 28.0±10.6 31.0±9.8 53.2±29.3 ＜0.001
b
COX-2: cyclooxygenase-2, VEGF: vascular endothelial growth fac-
tor, MVD: microvascular density, NI-BPH: noninflammatory be-
nign prostatic hyperplasia, I-BPH: inflammatory benign prostatic
hyperplasia, PC: prostate cancer, 
a: statistical analysis by Mantel- 
Haenszel chi-square test, 
b: statistical analysis by one-way ANOVA
FIG. 3. MVD in NI-BPH, I-BPH, and PC. Statistical analysis 
showed a significant increase in MVD in PC compared with NI-
BPH and I-BPH (p＜0.001). No significant difference was found
between NI-BPH and I-BPH (p=0.530). MVD: microvascular den-
sity, NI-BPH: noninflammatory benign prostatic hyperplasia, 
I-BPH: inflammatory benign prostatic hyperplasia, PC: prostate
cancer, 
a: statistical analysis by Tukey’s test.
than in BPH samples (Table 1, Fig. 1).
2. Immunohistochemical expression in NI-BPH, I-BPH, 
and PC
We divided the BPH specimens into NI-BPH and I-BPH 
subgroups. Overexpression of COX-2 was gradually increa-
sed in cases of NI-BPH, I-BPH, and PC (13.0%, 24.4%, and 
57.9%, respectively; p＜0.001). The overexpression of Bcl-2 
and VEGF also gradually increased (p＜0.001 and p= 
0.002, respectively). The apoptotic index and MVD showed 
significant differentiation in each group (p＜0.001, respec-
tively) (Table 2). Although the apoptotic index was higher 
in I-BPH (p＜0.001), there was no significant difference be-
tween NI-BPH and I-BPH (p=0.050) or between NI-BPH 
and PC (p=0.641) (Fig. 2). MVD was significantly higher 
in PC (p＜0.001), but there was no significant difference be-
tween NI-BPH and I-BPH (p=0.530) (Fig. 3).
3. Correlation between COX-2 overexpression and apop-
tosis
The mean apoptotic index of all cases studied was 2.0±2.5. 
The correlation between COX-2, Bcl-2, VEGF immunor-
eactivity, MVD, and the apoptotic index is summarized in 
Table 3. There was a significant correlation between the 
overexpression of COX-2 and Bcl-2 (p=0.001). However, the 
apoptotic index was not correlated with the overexpression 
of COX-2 or Bcl-2 (p=0.344 or p=0.927).
4. Correlation between COX-2 overexpression and angio-
genesis
The mean MVD of all cases studied was 40.9±24.2. There 
was a significant correlation between the overexpression 
of COX-2 and VEGF (p＜0.001). MVD was correlated with 
the overexpression of COX-2 (p＜0.001) and VEGF (p=0.040).Korean J Urol 2011;52:253-259
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TABLE 3. Correlation between COX-2 expression, Bcl-2 expression, VEGF expression, apoptotic index, and MVD
Cox-2 Bcl-2 Apoptotic index VEGF MVD
Cox-2 - 0.001
a 0.344
a ＜0.001
a ＜0.001
a 
Bcl-2 - 0.927
a 0.187
a 0.001
a
Apoptotic index -  0.005
a 0.656
a
VEGF - 0.040
a
MVD 　　 　 　 -　
COX-2: cyclooxygenase-2, VEGF: vascular endothelial growth factor, MVD: microvascular density, 
a: statistical analysis by Spearman
correlation analysis
DISCUSSION
The COXs are a family of myeloperoxidases, located on the 
luminal side of the endoplasmic reticulum and nuclear 
membrane, that catalyze the rate-limiting step of prosta-
glandin biosynthesis from arachidonic acid [15]. Prosta-
glandins, specifically, are important for physiological func-
tions such as vasodilatation (PGD2, PGE2, and PGI2), gas-
tric cytoprotection (PGI2), the maintenance of renal ho-
meostasis, and platelet aggregation. Prostaglandins also 
play a major role in mediating fever (PGE2), in pain sensi-
tivity, and in inflammation [15]. Overexpression of COX-2 
has been demonstrated to contribute to carcinogenesis by 
stimulating cell proliferation, inhibiting apoptosis, and en-
hancing angiogenesis; all of these effects are thought to be 
mediated via PGE2 [16-18].
　At present, COX-2 overexpression has been identified in 
many tumor tissues. As well, COX-2 overexpression is 
well-established in PC [5,9]. Madaan et al found expression 
of COX-2 in 74% of 82 cases of PC [5], Kirschenbaum et al 
reported expression of COX-2 in 63% of 31 cases [4], and 
Yoshimura et al found increased expression in 28 cases of 
PC [9]. Yet, research on the expression of COX-2 in human 
PC is still controversial. Zha et al conducted a large study 
analyzing 144 samples of PC as large sections or tissue-mi-
croarray cores and found them to be negative for COX-2 
[10]. On the other hand, COX-2 expression in a variety of 
pathologic prostate conditions has been studied. An in-
creased expression of COX-2 in atrophic areas (post-atro-
phic hyperplasia or proliferative inflammatory atrophy), 
which were associated with inflammation, has been de-
scribed in several publications [10-12]. Denkert et al ob-
served an overexpression of COX-2 in PC (44.7%) and pros-
tate intraepithelial neoplasia (72.1%) samples when com-
pared with benign prostatic tissue [13].
　In this study, overexpression of COX-2 was observed in 
PC compared with benign prostatic tissue, and the gradual 
expression of COX-2 was identified in NI-BPH, I-BPH, and 
PC. This is in line with the above-mentioned studies, which 
suggest that chronic inflammation may trigger COX-2 ex-
pression in the early stages of prostate carcinogenesis. 
　Apoptosis is important for the development and main-
tenance of tissue homeostasis of multicellular organisms 
[19,20]. An important factor in tumorigenesis is the bal-
ance between the proapoptotic and antiapoptotic members 
of the Bcl-2 family [21]. In a tumor cell, a mutation of the 
Bcl-2 gene, which results in increased expression, will sup-
press the normal function of the proapoptotic proteins 
Bcl-2-associated X protein (BAX) and Bcl-2 homologous an-
tagonist killer (BAK). On the other hand, if a mutation of 
the BAX or BAK genes causes a down-regulation of ex-
pression, then the cell will also lose its ability to regulate 
apoptosis-again causing tumorigenesis.
    In this study, a significant correlation between the over-
expression of COX-2 and Bcl-2 was identified, and their 
gradual overexpression was linked to chronic inflamma-
tion and carcinoma. We also found that the apoptotic index 
was high in BPH compared with PC. These data suggest 
that COX-2 overexpression in PC is associated with a de-
crease in apoptosis. In previous studies, the overexpres-
sion of COX-2 was found to increase the cellular levels of 
Bcl-2; therefore, it may cause resistance to apoptosis of pre-
malignant cells [21]. However, the mechanism by which 
COX-2 inhibition induces apoptosis is not well understood. 
Studies have suggested that decreased cellular PGE2 and 
increased arachidonic acid levels might be involved in the 
inhibition of cell proliferation and the induction of apopto-
sis [22].
    We divided the BPH cases into NI-BPH and I-BPH. The 
apoptotic index was higher in I-BPH than in NI-BPH or PC, 
although there were no significant differences between 
NI-BPH and I-BPH. Therefore, the apoptotic index was not 
correlated with overexpression of COX-2 and Bcl-2. 
Apoptosis is usually increased in inflammatory cells as a 
result of cell death mechanisms induced by cytotoxic lym-
phocytes [23]. Cell death can be caused by either necrosis 
or apoptosis. Cytotoxicity is an activity performed by speci-
alized cells such as natural killer cells and CD8+ T cells and 
is a highly organized multifactor process performed by dif-
ferent cells from the immune system [23]. We suggest that 
this multifactor process was a cause of the discordant apop-
totic index in this study.
　Cancer-induced angiogenesis is the result of increased 
expression of angiogenic factors, decreased expression of 
anti-angiogenic factors, or a combination of both events 
[24]. One of the mechanisms by which COX-2 acts as a tu-
mor promoter is through the stimulation of angiogenesis 
[25]. COX-2 was expressed in newly formed blood vessels 
within tumors grown in animals, whereas under normal 
physiological conditions the quiescent vasculature ex-Korean J Urol 2011;52:253-259
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presses only the COX-1 enzyme [26]. COX-2 modulates an-
giogenesis by augmenting the release of angiogenic pep-
tides, such as VEGF, thymidine phosphorylase, basic fibro-
blast growth factor (bFGF), and nitric oxide, by the tumor 
cells [25,27]. VEGF, a highly specific mitogen of vessel en-
dothelial cells, is the most potent tumor-angiogenic factor 
and is capable of promoting the proliferation and migration 
of endothelial cells as well as increasing vascular perme-
ability [28].
　In this study, overexpression of VEGF and high MVD 
were shown in PC compared with BPH. Furthermore, a sig-
nificant correlation between the overexpression of COX-2 
and VEGF was identified, and this gradual expression was 
associated with inflammation and carcinoma. We also 
found that MVD was higher in tissues positive for COX-2 
and VEGF.
　These data suggest that COX-2 may play a critical role 
in tumor angiogenesis. Recent studies demonstrate that 
COX-2 overexpression correlates with VEGF mRNA or 
protein production [29,30]. COX-2 overexpression has 
been detected in the angiogenic vasculature present within 
the tumors and preexisting vasculature adjacent to cancer 
lesions, suggesting that COX-2 may induce newly formed 
blood vessels to sustain tumor cell viability and growth.
CONCLUSIONS
We found that COX-2 overexpression in PC was correlated 
with a decrease in apoptosis and an increase in 
angiogenesis. Chronic inflammation of BPH causes the 
overexpression of COX-2, resulting in an increase in ex-
pression of Bcl-2 and VEGF. It is likely that chronic in-
flammation plays a role in the intermediate step of carcino-
genesis in the prostate. 
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